Who We Help

Our Value Proposition: aktaPD® is an open-architecture business consortium and international Life Science industry partner to private, academic, and government clients. aktaPD experts help to facilitate the development of meaningful products, including new chemical entities (NCEs), biosimilars, biologicals, cell therapies, beneficial bacteria, foods, diagnostics, medical tools, and devices.

Our Successes Include:

Placed executive level interim experts for over 50 clients

Played a key role in smooth acquisition by a Fortune 500 company

Helped raise $50M in venture capital

Helped several companies acquire millions in IPO funding

Assisted several companies’ conversions to E6 Compliance Regulations

Jump-started a difficult and complex first-in-human protocol for a neurological indication

Organized, designed, implemented, and followed through submission completion pre-INDs / INDs / BLAs for numerous clients

Engineered successful pre-IND meeting for a novel anti-cancer agent

Revised an entire development program for a unique product, facilitated site and subject enrollment, worked with FDA and DSMB to significantly accelerate enrollment goals, and helped raise capital--all of which increased the company’s valuation

Helped develop European Phase1b/2 clinical trials for a new molecular entity for rare neuro-inflammatory indications

Designed aggressive development plan, timelines, and cost analysis, from preclinical to POC, for several therapeutic areas, including orphan indications

Oversaw governance of five CROs, four data management outsourced providers, 22 vendors, and 63 in-house contractors, and performed simultaneous clinical trial management for two mid-sized companies

Achieved annual cost savings on clinical trial execution of 27.25%

Evaluated vendor experience and work product, resulting in cost savings and added value for privately-held company

Designed and implemented a virtual vendor management / procurement model

Took over medical supervision for an on-going international metastatic cancer program

Commercialized and branded implantation devices

Supported the expert selection of an RNA inhibitor platform technology’s first indications

Supervised the successful preclinical evaluation of a potential immunogenic compound

Helped guide a successful Complete Clinical Hold response for a rare disease indication

Subscribe and Follow

Have the latest akta Pharmaceutical Development news delivered right to your inbox. 
And we will never share your information.